• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.

作者信息

Powell M F, Foster L C, Becker A R, Lee W

机构信息

Institute of Pharmaceutical Sciences, Syntex Research, Palo Alto, California 94304.

出版信息

Pharm Res. 1988 Aug;5(8):528-32. doi: 10.1023/a:1015929610687.

DOI:10.1023/a:1015929610687
PMID:3244663
Abstract

The degradation of muramyldipeptides (MDPs) in aqueous solution obeys the rate law kobs = kH+aH+ + ko + kHO-aHO- and the Arrhenius equation. For example, the rate constants for degradation of N-acetylmuramyl-L-threonyl-D-isoglutamine, 3, at 25 degrees C are kH+ = 2.3 X 10(-6) M-1 sec-1, ko = 8.2 X 10(-10) sec-1, and kHO- = 0.19 M-1 sec-1. The degradation rates are dependent on the side-chain substituents; it is predicted that sterically hindered MDP compounds will show an extended shelf life in aqueous solution. Product studies in the weakly acid pH region (where the pH of maximum stability occurs) show that MDP compounds degrade largely by hydrolysis of the dipeptide side chain. These data show that MDP 3 exhibits a shelf life (t90) of greater than 2 years in aqueous solutions of pH 4-4.5, the pH of maximum stability.

摘要

相似文献

1
Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.
Pharm Res. 1988 Aug;5(8):528-32. doi: 10.1023/a:1015929610687.
2
Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue.疫苗佐剂胞壁酰二肽(MDP)的配方。1. 一种胞壁酰二肽类似物的无定形和结晶形式的表征。
Pharm Res. 1988 Aug;5(8):523-7. doi: 10.1023/a:1015977526617.
3
Studies on the stability of muroctasin and degradation products built under extreme conditions.
Arzneimittelforschung. 1988 Jul;38(7A):959-68.
4
Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.在正常大鼠和无胸腺裸鼠中,由N-乙酰胞壁酰-L-丙氨酰-D-异谷氨酰胺的6-O-酰基和N-酰基衍生物的水性形式诱导的急性和慢性多关节炎。
Lab Invest. 1986 Sep;55(3):337-46.
5
Enhanced stability of codeine sulfate: effect of pH, buffer, and temperature on the degradation of codeine in aqueous solution.硫酸可待因稳定性增强:pH值、缓冲液及温度对可待因在水溶液中降解的影响
J Pharm Sci. 1986 Sep;75(9):901-3. doi: 10.1002/jps.2600750917.
6
Stability of lidocaine in aqueous solution: effect of temperature, pH, buffer, and metal ions on amide hydrolysis.利多卡因在水溶液中的稳定性:温度、pH值、缓冲液和金属离子对酰胺水解的影响。
Pharm Res. 1987 Feb;4(1):42-5. doi: 10.1023/a:1016477810629.
7
Parenteral peptide formulations: chemical and physical properties of native luteinizing hormone-releasing hormone (LHRH) and hydrophobic analogues in aqueous solution.肠胃外肽制剂:天然促黄体生成激素释放激素(LHRH)及疏水类似物在水溶液中的化学和物理性质
Pharm Res. 1991 Oct;8(10):1258-63. doi: 10.1023/a:1015847628047.
8
Cefuroxime hydrolysis kinetics and stability predictions in aqueous solution.头孢呋辛在水溶液中的水解动力学及稳定性预测
J Pharm Sci. 1994 Apr;83(4):577-81. doi: 10.1002/jps.2600830427.
9
Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.合成的胞壁酰二肽(MDP)N-乙酰胞壁酰-L-丙氨酰-D-异谷氨酰胺的免疫佐剂作用。
Z Immunitatsforsch Immunobiol. 1978 Oct;155(1):87-92.
10
Efficient genetically controlled formation of antibody to a synthetic antigen [poly(LTyr, LGlu)-poly(DLAla)- -poly(LLys)] covalently bound to a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine).高效地通过基因控制形成针对与合成佐剂(N-乙酰胞壁酰-L-丙氨酰-D-异谷氨酰胺)共价结合的合成抗原[聚(L-酪氨酸,L-谷氨酸)-聚(D-丙氨酸)-聚(L-赖氨酸)]的抗体。
Proc Natl Acad Sci U S A. 1980 Aug;77(8):4933-7. doi: 10.1073/pnas.77.8.4933.

引用本文的文献

1
Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B.可吸入尺寸的聚(丙交酯-共-乙交酯)微球增强了体外T细胞对重组结核分枝杆菌抗原85B的反应。
Pharm Res. 2007 Oct;24(10):1834-43. doi: 10.1007/s11095-007-9302-8. Epub 2007 Jul 27.
2
Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.
Pharm Res. 1989 Sep;6(9):748-52. doi: 10.1023/a:1015915212195.

本文引用的文献

1
Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition.一种合成佐剂、N-乙酰胞壁酰肽以及与不同油载体及其组成相关的细菌二糖肽的致关节炎能力。
Infect Immun. 1980 Jul;29(1):70-5. doi: 10.1128/iai.29.1.70-75.1980.
2
The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance.非离子嵌段聚合物表面活性剂的佐剂活性。I. 亲水亲油平衡的作用。
J Immunol. 1981 Sep;127(3):1244-50.
3
Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice.
使用正常和免疫抑制小鼠,研究各种胞壁酰二肽类似物的体内抗假单胞菌和抗念珠菌活性与网状内皮系统碳清除率之间的相关性。
Infect Immun. 1982 Jan;35(1):105-10. doi: 10.1128/iai.35.1.105-110.1982.
4
o-Phthaldialdehyde precolumn derivatization and reversed-phase high-performance liquid chromatography of polypeptide hydrolysates and physiological fluids.邻苯二甲醛柱前衍生化及反相高效液相色谱法分析多肽水解产物和生理体液
J Chromatogr. 1983 Aug 26;266:471-82. doi: 10.1016/s0021-9673(01)90918-5.
5
The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers.非离子型嵌段聚合物表面活性剂的佐剂活性。II. 与三嵌段和八嵌段共聚物结构相关的抗体形成与炎症
J Immunol. 1984 Dec;133(6):3167-75.
6
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.细菌肽聚糖衍生物佐剂活性的最小结构要求。
Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317-25. doi: 10.1016/0006-291x(74)90458-6.
7
The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces.非离子嵌段聚合物表面活性剂的佐剂活性。III. 选定生物活性表面的表征。
Scand J Immunol. 1986 Mar;23(3):287-300. doi: 10.1111/j.1365-3083.1986.tb01970.x.
8
An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.一种佐剂制剂,可选择性地引发保护性同种型抗体的形成和细胞介导的免疫反应。
J Immunol Methods. 1986 Dec 24;95(2):157-68. doi: 10.1016/0022-1759(86)90402-3.
9
Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.
Vaccine. 1987 Sep;5(3):223-8. doi: 10.1016/0264-410x(87)90105-8.
10
Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue.疫苗佐剂胞壁酰二肽(MDP)的配方。1. 一种胞壁酰二肽类似物的无定形和结晶形式的表征。
Pharm Res. 1988 Aug;5(8):523-7. doi: 10.1023/a:1015977526617.